Home Compare EW vs RMD
Stock Comparison · Comparison

Edwards Lifesciences vs ResMed: Which Stock Looks Stronger in 2026?

ResMed holds the cleaner structural position, with the lead spread across valuation and growth. Edwards Lifesciences does not offset that deficit through any equally strong structural edge elsewhere. The market setup is currently leaning toward Edwards Lifesciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with ResMed, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both valuation and growth materially support the lead. ResMed Inc. leads by 33 points on the overall comparison score.

Trajectory Similarity
0.66
Moderately similar
Peer-set rank: #8
within Edwards Lifesciences Corporation's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The match is driven mainly by revenue growth trajectory and investment intensity.

Similarity drivers
revenue growth trajectoryinvestment intensity
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
EW
Edwards Lifesciences Corporation
54
Peer-Score
Signal qualityHigh
vs
RMD
ResMed Inc.
87
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: EW vs RMD Profitability 78 100 Stability 49 72 Valuation 41 84 Growth 44 86 EW RMD
Gap Ranking
#1 Valuation +43
#2 Growth +42
#3 Stability +23
#4 Profitability +22
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for EW and RMD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer EWRMD Relative valuation Structural strength

ResMed Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but ResMed Inc. still holds a clear edge.
Growth
On growth, the same pattern holds: both are strong, but ResMed Inc. still leads clearly.
Valuation — Dominant Gap
EW
41
RMD
84
Gap+43in favour of RMD

The multiple-based pricing edge comes from a forward P/E that is 5.6 turns lower.

What keeps the gap from being one-sided

Edwards Lifesciences Corporation still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

The lead is built on both valuation and growth, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the EW vs RMD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-growth comparisons

Explore how EW and RMD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.